Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation
Launched by CENTRAL INSTITUTE OF MENTAL HEALTH, MANNHEIM · Feb 2, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring new ways to help people quit smoking by combining sleep improvements with chess-based training. The researchers believe that better sleep can help strengthen the memory of quitting techniques, making it easier for smokers to succeed in their efforts to stop. Participants will be monitored while they sleep and will also undergo brain scans to see how these methods work. They will be divided into four groups, where some will do high-intensity interval training along with chess training, while others will not.
To join the study, participants should be between 18 and 75 years old and must have a severe tobacco use disorder, which means they have a strong addiction to smoking. They need to be able to communicate well and give consent to take part in the trial. However, individuals with serious health conditions, a history of brain injury, or who are currently pregnant cannot participate. Those who join can expect to be involved in physical activities, brain scans, and have their sleep monitored, all aimed at helping them quit smoking successfully.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • severe tobacco use disorder (TUD) according to DSM-5
- • sufficient ability to communicate with investigators and answer questions in both written and verbal format
- • ability to provide fully informed consent and to use self-rating scales
- • right-handedness
- • HIIT can be performed without the risk of side effect (medical sports check)
- Exclusion Criteria:
- • severe internal, neurological, and/or psychiatric comorbidities; other Axis I mental disorders other than TUD according to ICD-10 and DSM 5 (except for mild depression, i.e. F32.0, adjustment disorder and specific phobias) in the last 12 months
- • history of brain injury
- • severe physical diseases
- • common exclusion criteria for MRI (e.g. metal, claustrophobia)
- • positive drug screening (opioids, benzodiazepines, barbiturates, cocaine, amphetamines)
- • psychotropic medication within the last 14 days
- • pregnancy
About Central Institute Of Mental Health, Mannheim
The Central Institute of Mental Health (ZI) in Mannheim is a leading research institution dedicated to advancing the field of mental health through innovative clinical trials and scientific inquiry. With a focus on understanding the complexities of mental disorders, the ZI integrates interdisciplinary approaches to develop effective treatment strategies and improve patient outcomes. The institute is renowned for its state-of-the-art facilities, collaborative research environment, and commitment to ethical standards in clinical research. By fostering partnerships with academic institutions, healthcare providers, and industry stakeholders, the Central Institute of Mental Health aims to translate scientific discoveries into practical applications that enhance mental health care globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mannheim, Baden Württemberg, Germany
Mannheim, , Germany
Patients applied
Trial Officials
Sabine Vollstädt-Klein, Prof. Dr.
Principal Investigator
Central Institute of Mental Health, Mannheim
Gordon Feld, Dr.
Principal Investigator
Central Institute of Mental Health, Mannheim
Karen Ersche, Prof. Dr.
Principal Investigator
Central Institute of Mental Health, Mannheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials